BioinformaticsPLoS ONEPeer-reviewed
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
Melissa F. Adasme, Daniele Parisi, Kristien Van Belle…·Michael Schroeder
This paper identifies ibrutinib as a VEGFR2 inhibitor through structure-based drug repositioning, revealing its polypharmacological action beyond BTK.
29 citations